美國SEC再將8家中概股納預定除牌名單
格隆匯5月23日丨美國SEC將新一批8家在美國上市的中國公司列入“預定除牌名單(Provisional list)”,其中包括瑞思教育和醫美國際。該名單目前已增至近150家。美國SEC於當地時間5月20日將中國天然資源、瑞思教育、寺庫和醫美國際等8家中概股,列入預定除牌名單。此外Plastec Technologies則在5月13日遭納入。該會稱,被臨時認定的發行人若認為被認定錯誤,將有15個工作日與委員會工作人員聯繫,並應在信函中附上證據支持。上週五被列入的8家公司可在6月13日前提交證據,以證明被認定錯誤。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.